Cocaine: Mechanism, Clinical Uses, Adverse Effects

Mechanism of action

Cocaine produces local anesthesia through voltage-gated sodium channel blockade in peripheral nerves, preventing action potential generation and propagation. As an ester local anesthetic, it binds to the intracellular portion of sodium channels in their inactive state, stabilizing this conformation and raising the threshold for depolarization.

Cocaine's sympathomimetic effects result from inhibition of presynaptic reuptake of norepinephrine, dopamine, and serotonin at nerve terminals. By blocking the norepinephrine transporter (NET), dopamine transporter (DAT), and serotonin transporter (SERT), cocaine increases synaptic concentrations of these monoamines. The accumulation of norepinephrine at peripheral adrenergic synapses produces intense vasoconstriction and cardiovascular stimulation. Central dopamine accumulation, particularly in the nucleus accumbens and ventral tegmental area, mediates cocaine's reinforcing and addictive properties.

Cocaine is unique among local anesthetics for possessing intrinsic vasoconstrictive properties, eliminating the need for co-administration of epinephrine. This vasoconstriction reduces operative bleeding and prolongs the duration of local anesthesia by decreasing systemic absorption.

High-yield for exams

Cocaine is the only local anesthetic with intrinsic vasoconstrictive properties via catecholamine reuptake inhibition
Blocks sodium channels for local anesthesia and inhibits NET, DAT, and SERT for sympathomimetic effects
Beta-blockers are contraindicated in cocaine toxicity due to unopposed alpha-agonism causing severe hypertension
Cocaine-induced MI occurs via coronary vasospasm even in patients with normal coronary arteries
Metabolized by plasma pseudocholinesterase; deficiency increases toxicity risk
Ester local anesthetic: may cross-react with procaine, tetracaine, benzocaine but not amide anesthetics
Schedule II controlled substance; FDA-approved only for topical nasopharyngeal anesthesia
Alcohol co-use produces cocaethylene, a more cardiotoxic metabolite with longer half-life

Indications

Cocaine is FDA-approved exclusively for topical anesthesia of mucous membranes in the oropharynx, larynx, and nasal cavities. Clinical applications include:

Topical anesthesia and vasoconstriction for nasopharyngeal and laryngeal procedures
Otolaryngologic surgery requiring mucosal shrinkage and hemostasis
Nasal intubation procedures
Diagnostic nasopharyngoscopy and laryngoscopy

Cocaine solutions are typically applied to mucous membranes via pledgets, sprays, or direct application. Concentrations range from 1% to 10%, with 4% being most common. The dual anesthetic and vasoconstrictive effects make cocaine particularly useful in highly vascular nasal mucosa.

Cocaine has no role in infiltrative or regional anesthesia due to excessive toxicity risk. Other local anesthetics combined with epinephrine are safer alternatives for most applications. Cocaine is a Schedule II controlled substance under the Controlled Substances Act due to high abuse potential.

Pharmacokinetics

Cocaine is rapidly absorbed across mucous membranes, with peak plasma concentrations occurring 30-60 minutes after topical application. Systemic absorption depends on concentration, application site vascularity, and total dose. Nasal mucosa absorption approaches 80-90% bioavailability.

Cocaine undergoes extensive first-pass hepatic metabolism when absorbed systemically. It is hydrolyzed by plasma and hepatic esterases (primarily butyrylcholinesterase/pseudocholinesterase) to inactive metabolites benzoylecgonine and ecgonine methyl ester. A minor fraction is N-demethylated by hepatic cytochrome P450 3A4 to norcocaine, an active and potentially more cardiotoxic metabolite.

The elimination half-life is approximately 1 hour for cocaine itself, though metabolites persist longer and are detectable in urine for 2-4 days after single use. Patients with pseudocholinesterase deficiency are at increased risk for cocaine toxicity due to impaired metabolism and prolonged drug exposure.

Cocaine crosses the placenta readily and is distributed into breast milk, making it contraindicated in pregnancy and lactation outside of essential procedures with informed consent.

Adverse effects

Cocaine toxicity produces multisystem effects dominated by excessive sympathetic stimulation and local anesthetic systemic toxicity (LAST).

Cardiovascular toxicity

Cardiovascular effects are the most dangerous and include hypertension, tachycardia, coronary vasospasm, myocardial infarction (even in patients with normal coronary arteries), arrhythmias (ventricular tachycardia, ventricular fibrillation), and aortic dissection. Cocaine-induced myocardial infarction results from increased oxygen demand, coronary vasoconstriction, and prothrombotic effects. QRS widening and QT prolongation indicate severe sodium channel blockade.

Central nervous system toxicity

CNS effects include anxiety, agitation, euphoria, tremor, seizures, hyperthermia, and intracranial hemorrhage (from hypertensive crisis or rupture of underlying vascular malformations). Cocaine lowers the seizure threshold through dopaminergic and glutamatergic mechanisms.

Local effects

Repeated topical application causes mucosal ischemia and necrosis. Chronic intranasal cocaine abuse produces septal perforation, saddle-nose deformity, and palatal perforations.

Other effects

Rhabdomyolysis, acute kidney injury, hepatotoxicity, bowel ischemia (in body packers or stuffers), hyperthermia, and serotonin syndrome (when combined with serotonergic agents) may occur. Methemoglobinemia is rare but reported.

Pregnancy

Cocaine is associated with placental abruption, preterm labor, intrauterine growth restriction, and neonatal neurodevelopmental abnormalities.

Contraindications and warnings

Absolute contraindications include hypersensitivity to ester local anesthetics, severe cardiovascular disease (uncontrolled hypertension, recent myocardial infarction, unstable angina, severe coronary artery disease), uncontrolled hyperthyroidism, and pheochromocytoma.

Relative contraindications and warnings include:

Pregnancy and lactation (Category C; high risk of fetal harm)
Pseudocholinesterase deficiency (prolonged toxicity risk)
Concurrent MAO inhibitor therapy (hypertensive crisis risk)
Cerebrovascular disease or intracranial aneurysms (hemorrhage risk)
Seizure disorders (lowers seizure threshold)
Closed-angle glaucoma (mydriasis may precipitate acute attack)
Use in highly vascular or traumatized tissue increases systemic absorption

Maximum recommended topical doses are 1-3 mg/kg, with an absolute maximum of 200 mg in adults to minimize systemic toxicity risk. Lower doses should be used in elderly patients, those with cardiovascular disease, and patients with reduced pseudocholinesterase activity.

Cocaine should never be combined with epinephrine or other vasopressors due to synergistic cardiovascular toxicity. It should be avoided in patients with active substance use disorders when alternatives exist.

Healthcare facilities must maintain strict controlled substance protocols for cocaine storage, documentation, and administration.

Drug interactions

Cocaine has numerous clinically significant drug interactions:

Beta-blockers: Combined use results in unopposed alpha-adrenergic stimulation, causing severe hypertension, coronary vasospasm, and increased myocardial infarction risk. Selective beta-blockers (metoprolol, atenolol) pose greater risk than non-selective agents with alpha-blocking properties (labetalol, carvedilol).

MAO inhibitors: Potentiate sympathomimetic effects by preventing monoamine degradation, leading to hypertensive crisis. This interaction persists for 2 weeks after MAO inhibitor discontinuation.

Sympathomimetics: Additive cardiovascular toxicity with other sympathomimetic agents (ephedrine, pseudoephedrine, amphetamines, phenylephrine).

Anticholinesterase agents: Drugs that inhibit pseudocholinesterase (organophosphates, echothiophate, certain chemotherapy agents) prolong cocaine's half-life and increase toxicity risk.

Serotonergic agents: Combined use with SSRIs, SNRIs, MAO inhibitors, tramadol, or other serotonergic drugs increases serotonin syndrome risk.

Calcium channel blockers and nitrates: These agents are used therapeutically to manage cocaine-induced coronary vasospasm but should be used cautiously in the setting of hypotension.

Alcohol: Concurrent ethanol use produces cocaethylene through hepatic transesterification. Cocaethylene has longer half-life, greater cardiotoxicity, and increased lethality compared to cocaine alone.

QT-prolonging drugs: Additive risk of ventricular arrhythmias when combined with other QT-prolonging agents.

Cocaine interacts with CYP3A4 inhibitors (ritonavir, ketoconazole) and inducers (rifampin, carbamazepine), though clinical significance in topical use is limited.

Clinical pearls

Unique anesthetic property: Cocaine is the only local anesthetic with intrinsic vasoconstrictive effects, eliminating the need for epinephrine co-administration in topical applications.

Beta-blocker warning: Beta-blockers are relatively contraindicated in cocaine toxicity because they produce unopposed alpha-adrenergic vasoconstriction, worsening hypertension and coronary vasospasm. Benzodiazepines are first-line for cardiovascular symptoms.

MI in young patients: Consider cocaine use in any young patient presenting with acute myocardial infarction, especially with normal coronary anatomy. Cocaine-induced MI can occur hours after use as vasospasm and prothrombotic effects persist.

Pregnancy complications: Cocaine is a leading cause of placental abruption in drug-using populations and should be screened for in relevant clinical contexts.

Body packer syndrome: Patients who swallow cocaine packets for smuggling (body packers) are at extreme risk for massive toxicity if packets rupture. These cases require intensive monitoring and often surgical removal.

Treatment principles: Cocaine toxicity management prioritizes benzodiazepines for agitation and cardiovascular symptoms, cooling for hyperthermia, and avoiding beta-blockers. Chest pain is treated with benzodiazepines, aspirin, and nitrates or calcium channel blockers for persistent vasospasm.

Ester anesthetic allergies: True cocaine allergy is rare but may cross-react with other ester local anesthetics (procaine, tetracaine, benzocaine) but not amides (lidocaine, bupivacaine).

Pseudocholinesterase deficiency: These patients metabolize cocaine slowly, increasing toxicity risk even at standard topical doses.

Exam tip: When asked about local anesthetics with vasoconstrictor properties or anesthetics never combined with epinephrine, the answer is cocaine.

Mnemonic

Cocaine is the only local anesthetic that CONSTRICTS: Catecholamine reuptake inhibition causes Obvious vasoconstriction, Never needs epinephrine, Sympathomimetic Toxicity, Risky in Coronary disease, Inhibits pseudocholinesterase breakdown, Cardiotoxic, Topical use only, Seizures possible

Practice questions

1. A 28-year-old man is brought to the emergency department with severe chest pain, diaphoresis, and anxiety. His blood pressure is 185/110 mmHg, heart rate is 130/min, and temperature is 38.5°C (101.3°F). ECG shows ST-segment elevation in leads V2-V4. Urine drug screen is positive for cocaine. The physician considers administering a beta-blocker. Which of the following best explains why beta-blockers should be avoided in this patient?

Answer: B. Beta-blockers cause unopposed alpha-adrenergic receptor stimulation in cocaine toxicity. Cocaine increases synaptic norepinephrine, which activates both alpha and beta receptors. When beta-receptors are blocked, unopposed alpha-receptor activation leads to severe vasoconstriction, worsening hypertension and coronary vasospasm, increasing myocardial infarction risk. Benzodiazepines are the appropriate first-line treatment. Beta-blockers do not affect cocaine metabolism, absorption, or catecholamine degradation, and they do not interact with sodium channels.

2. A 45-year-old woman is scheduled for nasopharyngoscopy to evaluate chronic epistaxis. The otolaryngologist plans to use topical cocaine for anesthesia and vasoconstriction. Which of the following properties makes cocaine unique among local anesthetics for this procedure?

Answer: C. Cocaine is the only local anesthetic with intrinsic vasoconstrictive properties, achieved by blocking norepinephrine, dopamine, and serotonin reuptake at nerve terminals. This eliminates the need for co-administered epinephrine, making it particularly useful in highly vascular areas like nasal mucosa. Cocaine does not have the longest duration, does not selectively block specific nerve fiber types, is metabolized primarily by plasma esterases (not extensively by P450), and actually has higher systemic toxicity than most other local anesthetics.

3. A 32-year-old man presents to the emergency department with acute substernal chest pain that began 2 hours ago. He admits to intranasal cocaine use 3 hours prior. Troponin is elevated, and ECG shows ST elevations in the inferior leads. Coronary angiography demonstrates normal coronary arteries without atherosclerosis. Which of the following mechanisms best explains this patient's myocardial infarction?

Answer: C. Cocaine-induced myocardial infarction in patients with normal coronary anatomy results primarily from intense coronary vasospasm. Cocaine increases synaptic norepinephrine, which activates alpha-adrenergic receptors on coronary smooth muscle, causing vasoconstriction. This vasospasm reduces coronary blood flow and can cause transmural infarction even without underlying atherosclerosis. While cocaine does increase platelet aggregation and causes tachycardia, the primary mechanism in angiographically normal arteries is vasospasm. Sodium channel blockade causes arrhythmias but not direct MI, and endothelial disruption is not the primary mechanism.

Frequently asked questions

How does cocaine work as a local anesthetic?

Cocaine blocks voltage-gated sodium channels in peripheral nerves, preventing action potential generation and signal transmission. It also inhibits reuptake of norepinephrine, dopamine, and serotonin at nerve terminals, producing vasoconstriction and sympathomimetic effects. This dual mechanism makes cocaine unique among local anesthetics, as it is the only one with intrinsic vasoconstrictive properties, eliminating the need for co-administered epinephrine in topical applications.

What are the side effects of cocaine?

Cocaine's adverse effects are primarily cardiovascular and neurological. Cardiovascular toxicity includes hypertension, tachycardia, coronary vasospasm, myocardial infarction, arrhythmias, and aortic dissection. Central nervous system effects include anxiety, agitation, seizures, hyperthermia, and intracranial hemorrhage. Other complications include rhabdomyolysis, acute kidney injury, mucosal ischemia with chronic use, and in pregnancy, placental abruption and fetal complications. The severity of effects correlates with dose and route of exposure.

Is cocaine a controlled substance?

Yes, cocaine is a Schedule II controlled substance under the U.S. Controlled Substances Act due to its high potential for abuse and dependence. Despite this classification, it has accepted medical use for topical anesthesia and vasoconstriction in nasopharyngeal procedures. Healthcare facilities must maintain strict protocols for cocaine storage, inventory tracking, documentation, and administration to comply with federal and state regulations governing controlled substances.

Why are beta-blockers dangerous in cocaine toxicity?

Beta-blockers cause unopposed alpha-adrenergic receptor stimulation in cocaine toxicity, worsening hypertension and coronary vasoconstriction. Cocaine increases synaptic norepinephrine, which activates both alpha and beta receptors. When beta-receptors are blocked, the alpha-mediated vasoconstriction becomes unopposed, leading to severe hypertension, increased coronary vasospasm, and higher myocardial infarction risk. Benzodiazepines are the preferred first-line treatment for cocaine-induced cardiovascular symptoms because they reduce sympathetic outflow without this risk.

Cocaine vs lidocaine — what is the difference?

Cocaine is an ester local anesthetic with intrinsic vasoconstrictive properties, while lidocaine is an amide without vasoactive effects. Cocaine blocks sodium channels and inhibits catecholamine reuptake, producing both anesthesia and vasoconstriction, whereas lidocaine requires co-administered epinephrine for vasoconstriction. Cocaine is used only topically on mucous membranes due to high toxicity, while lidocaine is used topically, via infiltration, and for regional blocks. Cocaine is a Schedule II controlled substance; lidocaine is not. Cocaine is metabolized by plasma esterases; lidocaine by hepatic CYP enzymes.

Conditions it is used for

Topical anesthesia for nasopharyngeal proceduresMucosal anesthesia for laryngoscopyVasoconstriction for otolaryngologic surgeryAnesthesia for nasal intubation

lidocaineprocainetetracainebenzocainebupivacaineprilocaineepinephrinephenylephrine

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlus WHO ATC/DDD index: N01BC01 WHO ATC/DDD index: R02AD03

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.

Cocaine